79562-49-5

Basic information

• Product Name: 1,3-difluoro-2-methyl-4-nitrobenzene
• Synonyms: 1,3-difluoro-2-methyl-4-nitrobenzene;2,6-Difluoro-3-nitrotoluene
• CAS NO: 79562-49-5
• Molecular Formula: C₇H₅F₂NO₂
• Molecular Weight: 173.117
• Mol File: 79562-49-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 237.2 °C at 760 mmHg
• Flash Point: 108.8 °C
• Appearance: /Solid
• Density: 1.374 g/cm³
• Vapor Pressure: 0.07mmHg at 25°C
• Refractive Index: 1.508
• Storage Temp.: Sealed in dry,Room Temperature
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 1,3-difluoro-2-methyl-4-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-difluoro-2-methyl-4-nitrobenzene(79562-49-5)
• EPA Substance Registry System: 1,3-difluoro-2-methyl-4-nitrobenzene(79562-49-5)

Safety Data

• RIDADR: UN2811
• HazardClass: 6.1
• Hazardous Substances Data: 79562-49-5(Hazardous Substances Data)

Usage

Description

1,3-difluoro-2-methyl-4-nitrobenzene is an organic compound that features a benzene ring with two fluorine atoms at the 1 and 3 positions, a methyl group at the 2 position, and a nitro group at the 4 position. 1,3-difluoro-2-methyl-4-nitrobenzene is known for its potential applications in various fields due to its unique chemical structure and properties.

Uses

Used in Organic Synthesis:
1,3-difluoro-2-methyl-4-nitrobenzene is used as an intermediate in organic synthesis for the production of various chemical compounds. Its presence of fluorine and nitro groups allows for a range of reactions that can lead to the formation of diverse organic molecules.
Used in Pharmaceutical Research:
In pharmaceutical research, 1,3-difluoro-2-methyl-4-nitrobenzene is utilized as a key intermediate for the development of new drugs. Its unique structure can be modified to create potential drug candidates with specific therapeutic properties.
Used in Chemical Research:
1,3-difluoro-2-methyl-4-nitrobenzene is also used in chemical research to study the effects of fluorination and nitration on the reactivity and stability of aromatic compounds. This can lead to a better understanding of chemical reactions and the development of new synthetic methods.

InChI:InChI=1/C7H5F2NO2/c1-4-5(8)2-3-6(7(4)9)10(11)12/h2-3H,1H3

Upstream product

• 443-84-5 2,6-difluorotoluene 

Downstream Products

• 485832-96-0 3-fluoro-2-methyl-6-nitroaniline 
• 1020173-29-8 2-fluoro-3-methyl-4-[2-(1-methyl-1H-pyrazol-4-yl)-pyridin-4-yloxy]-phenylamine 
• 1020173-28-7 4-(2-chloro-pyridin-4-yloxy)-2-fluoro-3-methyl-phenylamine 
• 1020173-27-6 4-amino-3-fluoro-2-methyl-phenol 
• 1393177-52-0 4-fluoro-3-methyl-N₂-phenylbenzene-1,2-diamine 
• 1393177-51-9 (3-fluoro-2-methyl-6-nitrophenyl)phenylamine 
• 1176335-25-3 cyano-(3-fluoro-2-methyl-4-nitro-phenyl)-acetic acid tert-butyl ester 
• 1068604-80-7 C₁₄H₈ClFN₂O₃ 
• 1020173-26-5 1-benzyloxy-3-fluoro-2-methyl-4-nitro-benzene 
• 76350-70-4 2,4-difluoro-3-methyl-aniline 
• 79562-50-8 2-[(2,4-Difluoro-3-methyl-phenylamino)-methylene]-malonic acid diethyl ester 

Relevant articles and documents

IMIDAZOLIDINONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Described are compounds of Formula I which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilic syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases.

KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES

The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.